The SCF/KIT signaling pathway in multisystem diseases: Mechanisms and therapeutic targeting. (PubMed, Sci Prog) - Sep 30, 2026 - "Clinically established KIT-directed tyrosine kinase inhibitors, including imatinib for mutation-sensitive GIST and midostaurin or avapritinib for advanced systemic mastocytosis, have transformed disease management. Mutation-dependent drug sensitivity, polyclonal secondary resistance, multikinase-related toxicity, and on-target effects in normal KIT-dependent tissues remain major challenges. A disease-, genotype-, and cell-specific framework is therefore essential for translating SCF/KIT biology into safe and effective precision therapies."
Journal • Review • Dermatology • Gastrointestinal Stromal Tumor • Immunology • Oncology • Sarcoma • Urticaria • KIT
|
|
Ruidie Ma; Xueliang Wang; Yingbing Mei
|